COVID-19 Records

Attachment

Gates Package, p.832 · gates:exh:00272

Page text: p.832 · original PDF

Date
(unknown precision)
Type
attachment · document
Topics
Intelligence community assessmentsProximal Origin paper
16. Wang H, Li C, Obadan AO, Frizzell H, Hsiang TY, Gil S, et al. In Vivo Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor. Hum Gene Ther. 2022;33(7-8):389-403. 17. Lattanzi A, Camarena J, Lahiri P, Segal H, Srifa W, Vakulskas CA, et al. Development of beta-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med. 2021;13(598). 18. Stamatoyannopoulos G, Wood WG, Papayannopoulou T, and Nute PE. A new form of hereditary persistence of fetal hemoglobin in blacks and its association with sickle cell trait. Blood. 1975;46(5):683-92. 19. Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, et al. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2021;384(3):205-15. 20. Wu Y, Zeng J, Roscoe BP, Liu P, Yao Q, Lazzarotto CR, et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med. 2019;25(5):776-83. 21. Weber L, Frati G, Felix T, Hardouin G, Casini A, Wollenschlaeger C, et al. Editing a gamma-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. Sci Adv. 2020;6(7). 22. Peterson KR, Navas PA, and Stamatoyannopoulos G. beta-YAC transgenic mice for studying LCR function. Ann N Y Acad Sci. 1998;850:28-37. 23. Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nature medicine. 2018;24(7):939-46. 24. Kosicki M, Tomberg K, and Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nature biotechnology. 2018;36(8):765-71. 25. Haapaniemi E, Botla S, Persson J, Schmierer B, and Taipale J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nature medicine. 2018;24(7):927-30. 26. Newby GA, and Liu DR. In vivo somatic cell base editing and prime editing. Mol Ther. 2021;29(11):3107-24. 27. Song Y, Liu Z, Zhang Y, Chen M, Sui T, Lai L, et al. Large-Fragment Deletions Induced by Cas9 Cleavage while Not in the BEs System. Mol Ther Nucleic Acids. 2020;21:523-6. 28. Webber BR, Lonetree CL, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers MD, et al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun. 2019;10(1):5222. 29. Newby GA, Yen JS, Woodard KJ, Mayuranathan T, Lazzarotto CR, Li Y, et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature. 2021;595(7866):295-302.